GSK Vaccines’ investigational meningococcal vaccine against serogroups A, B, C, W and Y (MenABCWY) is broadly effective among adolescents, according to the company’s phase 2b, observer-blind, multicenter study, reported at IDWeek 2016.
Opportunities to vaccinate against Hepatitis A virus were missed in more than half of patients with HIV and Hepatitis C virus co-infection, researchers reported at IDWeek 2016.
GSK’s investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) “demonstrated an acceptable immune response” that was non-inferior to Merck’s MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.
An investigational herpes zoster subunit vaccine significantly reduces disease risk as well as severity in those who develop breakthrough disease in adults 50 years and older
Population level-analyses between 2003-2013 found no links between sudden infant death syndrome (SIDS), attention-deficit/hyperactivity disorder (ADHD), and vaccines, Jana Shaw, MD, MPH, Associate Professor of Pediatrics, Pediatric Infectious Diseases, Upstate Golisano Children’s Hospital, State University of New York, Syracuse, NY, presented at IDWeek 2016.
During the 2013-2014 A/H1N1 dominant flu season, Fluzone High-Dose vaccine reduced the risks of all-cause hospitalization and hospitalization for respiratory conditions among long-term care residents compared with Fluzone standard-dose vaccine, investigators reported at IDWeek.
A multinational retrospective analysis failed to confirm a possible association between pediatric narcolepsy and the AS03- and MF-59-adjuvanted monovalent pandemic H1N1 vaccines.
The meningococcal Serogroup B vaccine MenB-FHbp (Bivalent rLP2086) induces immunogenicity in young people age 10 to 18.
Safety profiles for elderly people are similar for simultaneous and sequential administration of quadrivalent influenza vaccine (QIV) and 23-valent pneumococcal polysaccharide vaccine (PPV).
Different dosing schedules for a two-dose candidate herpes zoster (HZ) subunit vaccine (HZ/su) exhibited similar immunogenicity and safety profiles among older adults, authors of a randomized, open-label, multicenter phase 3 study reported at IDWeek 2016.
Please login or register first to view this content.
